Kornimate/medical-research-clean huggingface dataset:
microbiologic response with linezolid and vancomycin in ventilator-associated pneumonia due to methicillin resistant staphylococcus aureus

Conditions: Pneumonia, Ventilator-Associated

Summary: ventilator-associated pneumonia (vap) is a commonplace complication of intensive care patients ventilated for longer than 48 hours. methicillin-resistant staphylococcus aureus (mrsa) is the cause of late onset vap in up to about 30% of cases in us hospitals. ineffective treatment of mrsa vap clearly leads to prolonged mechanical ventilation and is probably associated with higher mortality. the purpose of this protocol is to directly compare linezolid and vancomycin specifically for mrsa vap.


Eligibility criteria:
inclusion criteria: * the patient must have or be suspected of having a ventilator-associated pneumonia (vap) due to mrsa. * patient must be hospitalized for at least 5 days, must be ventilator-dependent ≥ 48 hours prior to screen/baseline, and anticipated to remain on the ventilator for 72 hours after enrollment so follow-up bal can be performed. * clinical picture compatible with pneumonia (acquired during ventilation) * chest x ray at baseline/screen or within 24 hours of initiation of therapy must be consistent with diagnosis of pneumonia exclusion criteria: * hypersensitivity to linezolid, vancomycin, or one of the excipients in any of these drug formulations. * infections due to gram-positive organisms known to be resistant to either of the study drugs. * any antibiotic used in the treatment of mrsa, such as vancomycin, tmp/smx, rifampin, or linezolid, for more than 48 hours prior to patient's enrollment into the study. * patients with neutropenia, aids, lymphoma or anticipated chemotherapy. * patients who have long-term tracheostomy (for more than 60 days). acute tracheostomy patients are allowed.
renal effects of levosimendan in patients admitted with acute decompensated heart failure

Conditions: Heart Failure; Renal Insufficiency

Summary: the purpose of this study is to evaluate the effect of levosimendan infusion, in addition to standard therapy,on renal function in patients with acute heart failure,compared with standard therapy alone.

the term "cardiorenal syndrome" has been applied to the presence or development of a renal dysfunction in hf patients and may be the major precipitant of decompensation and cause for admission in these patients. the renal hypoperfusion that occurs with cardiac injury can lead to sodium and water retention and activation of the renin-angiotensin-aldosterone system and neurohormonal pathways with resultant deleterious effects on the myocardium. a vicious cycle may then ensue and be associated with increased cardiovascular complications. in this regard, renal dysfunction is of a functional nature and thus means to intervene with this vicious cycle need to be sought. several studies already demonstrated the deleterious effects of renal dysfunction on prognosis in patients with hf due to chronic left ventricular dysfunction. levosimendan increases myocardial contractility without significant changes in the intracellular calcium ion and cyclic adenosine monophosphate concentrations and does not enhance myocardial oxygen demand. by its action on the potassium channels this drug also dilates the coronary and peripheral arteries and exerts an anti-ischemic,anti-stunning effect. to date, the effects of levosimendan on renal function in patients with worsening chronic hf, remain unknown.

Eligibility criteria:
inclusion criteria: * an ejection fraction (ef) 40% by transthoracic echocardiogram, * a baseline pulmonary capillary wedge pressure (pcwp) 20 mm hg * a mdrd (modification of diet renal disease) score \> 30 and \< 60 * and a standard therapy for hf that should include angiotensin converting enzyme inhibitors, angiotensin receptor blockers, aldosterone blocking agents (spironolactone) and beta-blockers, unless contraindicated exclusion criteria: * patients receiving other oral or i.v. inotropes, * oral or i.v. diuretics * or receiving nitroglycerine or nitroprusside, * patients with systolic blood pressure \<110 mmhg, * mechanical ventilation, * anticipated survival \<30 days, * absence of thoracic windows for echocardiography, * acute coronary syndromes, * sustained ventricular tachycardia or ventricular fibrillation, * documented renal artery stenosis, requiring dialysis, * requiring admission primarily for concurrent morbidity, * severe aortic or mitral regurgitation, * left ventricular failure primarily from uncorrected obstructive valvular disease, hypertrophic obstructive cardiomyopathy, restrictive/obstructive cardiomyopathy, * uncorrected thyroid disease, * known amyloid cardiomyopathy * or known malfunctioning artificial heart valve.

Keywords: cardiorenal syndrome
study of tumor tissue samples from patients who have undergone surgery for advanced stage iii or stage iv ovarian epithelial cancer

Conditions: Stage IIIA Ovarian Cancer; Stage IIIB Ovarian Cancer; Stage IIIC Ovarian Cancer; Stage IV Ovarian Cancer

Summary: this research study is looking at tumor tissue samples from patients who have undergone surgery for advanced stage iii or stage iv ovarian epithelial cancer. studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn how tumor infiltrating t cells can predict how patients will respond to treatment.

primary objectives: i. to validate the ability of intratumoral tumor-infiltrating t lymphocytes (tils) to predict progression-free survival (pfs) in patients with suboptimally debulked advanced stage iii or iv ovarian epithelial cancer. ii. to validate the ability of intratumoral tils to predict pfs in patients with optimally debulked disease. secondary objectives: i. to validate the ability of intratumoral tils to predict overall survival of patients with suboptimally debulked disease. ii. to validate the ability of intratumoral tils to predict overall survival of patients with optimally debulked disease. outline: patients are stratified according to status of debulked disease (suboptimal vs optimal). previously collected tumor tissue samples are analyzed for tumor-infiltrating lymphocytes (til) via immunohistochemistry and double immunofluorescence assays using standard immunostaining.

Eligibility criteria:
inclusion criteria: * diagnosis of stage iii or iv ovarian epithelial cancer and enrolled on gynecologic oncology group (gog)-0136 and a gog front-line platinum/taxol chemotherapy trial (gog-0114, gog-132, gog-0158, or gog-0162) * must have fixed and paraffin-embedded tissue from primary surgery available from 1 of the following sources: * patients enrolled on gog-0136 and a gog front-line platinum/taxol chemotherapy trial(gog-0114, gog-0132, gog-0158, and gog-0162) * patients who have had either optimal or suboptimal cytoreductive surgery * patients for whom adequate demographic data, including major prognostic factors and follow-up information, were collected * evaluable patients must have had measurable or nonmeasurable disease * demographic and follow-up data available
evaluation of satisfaction in patients receiving pegintron pen/rebetol for hepatitis c (study p04067)

Conditions: Hepatitis C, Chronic

Summary: the current gold standard for treatment of chronic hepatitis c (chc) patients is with pegylated interferon plus ribavirin. drug administration accuracy and ease of use will definitely determine treatment effectiveness. this is the idea behind the development and usage of the pegpen. the goal of this study is to determine the satisfaction grade with this novel device.

enrollment of patients will occur in a sequential order of treatment initiation.

Eligibility criteria:
inclusion criteria: * adult patients with hepatitis c exclusion criteria: * according to the products' labeling.
subcutaneous immunoglobulin treatment of patients with chronic inflammatory demyelinating polyradiculoneuropathy (cidp)

Conditions: Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

Summary: the purpose of this study is to determine whether subcutaneous immunoglobulin given in small doses, is effective in maintaining the force, in patients with chronic inflammatory demyelinating polyradiculoneuropathy compared with placebo (saline infusions), and intravenous immunoglobulin.

cidp is an autoimmune disease of the peripheral nervous system, responding well to treatment with intravenous immunoglobulin (ivig), steroids and plasmapheresis. ivig is effective in treating patients with cidp, but most of the patients need long time maintenance treatment, which is associated with decreased autonomy and regular hospital admissions. furthermore many of the patients complain of infusion related side effects such as headache, chills and fatigue, and over time there is problems obtaining intravenous entry because of occlusion of the veins. there is therefore a critical need for alternative methods to ivig treatment. the aim of this study is to evaluate the efficacy, tolerability and safety of small doses of immunoglobulin administered subcutaneously (scig), compared with placebo. at the same time we compare the efficacy of scig with the regular ivig treatment. we therefore hypothesize, 1: scig is better than subcutaneous placebo infusions, and is as good as ivig in maintaining muscle function in patients with cidp. 2: scig home treatment is safe and tolerable. 3: scig home treatment is preferred to ivig under hospital admission, by the patients.

Eligibility criteria:
inclusion criteria: * all patients with typical or pure motor cidp, who meet the clinical or electrophysiological criteria of the efns/pns for certain or probable cidp and who are in regular treatment with ivig on one of the neurological departments in denmark, are eligible for the study exclusion criteria: * pregnancy * known cancer disease * severe medical diseases * other immuno modulating treatment than low-dose steroid (prednisolone \< 25 mg/day) within the last 6 weeks before inclusion * hepatitis b or c or hiv * breast-feeding * non-responding to treatment with intravenous immunoglobulin * known hypersensitivity to intravenous immunoglobulins or kiovig adverse events: * previous moderate headache or minor rash for a few days during or after infusion is not an exclusion criteria * in case of severe adverse effects to treatment patients are excluded. moderate or mild side-effects can be treated with analgetics or steroids for 1-2 weeks during the initial study phase

Keywords: polyradiculoneuropathy, chronic inflammatory demyelinating subcutaneous immunoglobulin
impact of spiroergometer parameters as diagnostic marker of cardiac ischemia in pts. with stable angina compared to ffr.

Conditions: Stable Angina

Summary: in patients with stable angina pectoris ccs 1-3 exercise testing for ischemia detection is widely used despite the known limitations. measurement of the ffr is invasive but gold standard for ischemia detection. adding of parameters of spiroergometer might help to improve diagnostic accuracy of non invasive exercise testing. therefore the trial is evaluating diagnostic accuracy of spiroergometric parameters compared to invasive ffr measurement.


Eligibility criteria:
inclusion criteria: * stable angina (ccs \>1-3) with suspected cad or * dyspnoea at exertion nyha \>2 or * signs of ischemia within spect or exercise electrocardiography * willingness to participate in the trial exclusion criteria: * unstable angina or myocardial infarction within the last 2 weeks * inability to perform bicycle exercise test * significant valvular disease * hocm * av- block \>i degree * asthma bronchiales

Keywords: ffr measurement; exercise testing, ergospirometer
the study will evaluate if leuprolide mesylate is safe and effective in the treatment of subjects with advanced prostate carcinoma, when administered as two injections six months apart.

Conditions: Advanced Prostate Cancer

Summary: evaluate the safety, efficacy and pharmacokinetics of leuprolide injectable emulsion in advanced prostate cancer


Eligibility criteria:
inclusion criteria: * after having the scope and nature of the study explained, subjects must voluntarily sign the icf prior to the screening visit and be willing to comply with the study requirements and cooperate with all scheduled tests * male, aged ≥ 18 years old. * pathologically confirmed advanced prostate cancer candidate for androgen deprivation therapy, including patients those who have undergone radical treatment (surgical resection, external radiotherapy, or cryotherapy). exclusion criteria: * received or are undergoing androgen deprivation therapy (surgical castration or drug androgen deprivation therapy including but not limited to gonadotropin-releasing hormone \[gnrh\] receptor agonists, gnrh receptor antagonists, estrogen and progesterone and their analogs, androgen receptor antagonists, androgen synthesis inhibitors, etc.). * major surgery (including but not limited to radical prostatectomy, etc.), radiotherapy, chemotherapy, immunotherapy, cryotherapy, etc. within 4 weeks prior to the screening visit, or plan to receive the above treatments during the study * receipt of any vaccination within 4 weeks prior to first dose (except covid-19 vaccination).
prediction of cervical lymph node metastasis in papillary thyroid carcinoma based on ultrasound and cytological images

Conditions: Papillary Thyroid Carcinoma; Lymph Node Metastasis

Summary: rising thyroid carcinoma rates, with papillary thyroid carcinoma (ptc) as the main type (85-90% of cases), often show early cervical lymph node spread. this increases the risk of ptc patients for recurrence and death. a new study's multimodal model fuses preoperative us and cytology images to better predict lymph node metastasis, aiming to improve treatment plans, reduce unnecessary surgeries, and enhance patient outcomes.

thyroid carcinoma incidence has been on the rise in recent years. papillary thyroid carcinoma is the most prevalent type of differentiated thyroid carcinoma, accounting for 85% to 90% of malignant thyroid tumors. despite its indolent nature, cervical lymph node metastasis is frequently observed at an early stage. papillary thyroid carcinoma patients with cervical lymph node metastasis face an elevated risk of recurrence, distant metastasis, and mortality. thus, non-invasive preoperative prediction of cervical lymph node metastasis is particularly vital for guiding treatment plans and prognostic. this study has developed a multimodal model integrating preoperative us images with cytological images of papillary thyroid carcinoma patients. the aim is to enhance the predictive accuracy for cervical lymph node metastasis, reduce unnecessary lymph node dissections, and provide real-time, precise guidance for determining the extent of surgical resection and prognostic assessment. this approach aims to optimize patient treatment strategies and enhance therapeutic outcomes.

Eligibility criteria:
inclusion criteria: * underwent thyroidectomy and bilateral lymph node dissection with pathological confirmation of ptc * completed us examination within one week before surgery * underwent preoperative us-guided fnac * completed cytological images at 400× magnification under a microscope exclusion criteria: * patients who underwent only unilateral thyroidectomy * patients with cervical lymph nodes shown on preoperative ultrasound

Keywords: ultrasound deep learning cytology
partial versus total fundoplication in the surgical repair of para-esophageal hernia.

Conditions: Paraesophageal Hernia; Gastro Esophageal Reflux

Summary: short-term follow up after surgery of para-esophageal hernia comparing two different types of fundoplication

laparoscopic para-esophageal hernia (peh) repair has been established as a safe and effective treatment for symptomatic patients. today, most surgeons agree that a fundoplication should be included in the hiatal reconstruction in order to reduce the risk of postoperative gastroesophageal reflux and hernia recurrence. however, what type of wrap that should be recommend is yet to be determined. one might argue that the overall durability and effectiveness of a partial fundoplication in the control of reflux might be less reliable than a total wrap, but on the contrary, the latter carries the risk of inducing a pseudoachalasia similar situation in peh patients. we therefore designed a double blind randomized clinical trial in which patients with symptomatic paraesophageal hernia to receive either a posterior partial (toupet) or total (nissen) fundoplication after hernia reduction and crural repair. six months follow up with questionnaires, 24-hour ph monitoring and radiology after surgery of para-esophageal hernia with addition of total fundoplication vs posterial partial fundoplication. dysphagia scores; ogilvie dysphagia score and watson dysphagia score. quality of life; sf-36: physical and mental component scores. time points: 1, 3 and 6 months after surgery

Eligibility criteria:
inclusion criteria: * patients undergoing acute or elective surgery for symptomatic peh at ersta hospital and karolinska university hospital exclusion criteria: * age below 18 years * axial sliding hiatal hernia only (type i) * missing informed consent * previous hiatal hernia surgery * american society of anesthesiologists (asa) score iv or above * achalasia * zollinger-ellison syndrome * malignant tumor * inability or unwillingness to complete questionnaires

Keywords: nissen fundoplication toupet fundoplication crural repair quality of life
mirnas evaluating lymphocyte proliferation and apoptosis as well as prognosis of sepsis

Conditions: T Lymphocyte Disorder

Summary: sepsis is a systemic inflammatory reaction caused by infection, trauma, etc. in the process of sepsis, the apoptosis of lymphocyte serves as a vital factor of immune dysfunction. micro-rnas (mirnas) are endogenous small non-coding rna molecules. our previous studies have showed the diagnostic and prognostic value of a series circulant mirnas in human serum in sepsis. the present research further study the regulatory mechanism of those mirnas in lymphocyte in sepsis. our research is based on the clinical value of mir-223, mir-15a, mir-16. the investigators discuss the potential role of mir-223, mir-15a, mir-16 in regulating the proliferation and apoptosis of lymphocyte in sepsis and aim to find new targets for sepsis treatment.

blood samples were collected from the chinese people's liberation army general hospital. the investigators collected samples in emergency intensive care unit (eicu), surgical intensive care unit (sicu) and respiratory intensive care unit (ricu) between july 2014 to march 2015. septic patients were divided into sepsis, severe sepsis and septic shock according to the diagnostic criteria. peripheral white blood cells were sorted into monocytes, lymphocytes and neutrophils by using flow cytometry (flow cytometry, fcm). jurkat t cell lines were purchased from chinese academy of medical sciences institute of basic medical sciences. mirnas agomirs and antagonists were used to establish mir-223, mir-15a, mir-16 overexpression and knock-out transient transfection cell lines. western blot was used to detect difference expression of protein expression.

Eligibility criteria:
inclusion criteria: * diagnosis of sepsis * agree with this study exclusion criteria: * age \<18 years * died within 24 hours * combined with hiv infection * agranulocytosis

Keywords: sepsis micrornas
survey on long-term use of bi-sifrol® tablets in patients with restless legs syndrome

Conditions: Restless Legs Syndrome

Summary: the survey is conducted to investigate the safety and efficacy of long-term use of bi-sifrol tablets in restless legs syndrome (rls) patients with or without renal dysfunction in routine medical practice.


Eligibility criteria:
inclusion criteria: patient with restless legs syndrome exclusion criteria: none
online social networking for hiv prevention

Conditions: HIV

Summary: in this randomized controlled trial, we will identify social networks on facebook, an randomly assign each network to control or intervention status. we will then intervene at the level of the network with dynamic, interactive hiv prevention messages (intervention) or static messages about hiv prevention (control). we will develop the intervention content with input from our target audience (facebook users) and will measure baseline, and 3 and 6 month assessments of condom use and abstinence among all participants


Eligibility criteria:
inclusion criteria: * facebook user with an existing facebook page * at least 16 * no older than 24 * english speaker exclusion criteria: * older than 24 or younger than 16 * non english speaker * does not have a facebook page

Keywords: hiv prevention social networking technology based intervention
comparing injection frequency between aflibercept and ranibizumab in patients with crvo with a treat& extend regimen

Conditions: Central Retinal Vein Occlusion

Summary: comparing ranibizumab and aflibercept in a treat and extend algorithm evaluating the number of needed injections over a 18 month period in patients with newly diagnosed crvo.

forty patients diagnosed with a new central retinal vein occlusion (crvo) of a maximum duration of 6 months will be recruited to the study. patients will be randomized 1:1 to treatment with aflibercept ot ranibizumab. all patients will receive 3 initial monthly injections. there after injections will be given att every visit according to a treat and extend schedule. if no macular edema is seen on the ocular coherent tomography (oct) examination the next treatment will be after 6 weeks. if the macula is dry after 6 weeks a new injection is given and the next visit is scheduled for another 8 weeks. if edema is seen on the oct after 8 weeks the time to next injection is reduced to 6 weeks. patients cannot receive an injection more often than every 4 weeks. all patients will receive an injection at least every 12 weeks. primary outcome: the number of needed injections over a 18 month period comparing ranibizumab and aflibercept. secondary outcome: change in visual acuity, change in macular thickness. a subgroup of patients will also be evaluated with oct angiography. a possible relationship between the visual acuity and the foveal avascular zone will be evaluated.

Eligibility criteria:
inclusion criteria: * crvo - naive patients, disease duration maximum 12 months, best corrected visual acuity : 23-73 letters (20/40 - 20/320), macular edema \> 300 μm (cirrus) exclusion criteria: * neovascular glaucoma any previous treatment for crvo. intraocular surgery during the previous 3 months. vascular retinopathy of other causes. glaucoma with uncontrolled iop (intra ocular pressure) myocardial infarction or stroke during the last 3 months.
salpingectomy vs tubal sterilisation in low risk for ovarian cancer women and its effect on ovarian reserve

Conditions: Ovarian Cancer

Summary: randomised study to investigate if salpingectomies done to women wishing tubal sterilisation has an effect on ovarian reserve.


Eligibility criteria:
inclusion criteria: * women seeking for tubal sterilisation exclusion criteria: * women older than 45 * family history of ovarian cancer * presence of menopausal symptoms * irregular cycles * hormone replacement therapy or hormone contraceptions the last 3 months * history of previous ovarian or uterine surgeries * imaging suggesting an ovarian cyst or other adnexal pathology during investigation * previous salpingectomy